Intersectin 2, a new multimodular protein involved in clathrin-mediated endocytosis11The sequence data reported in this paper have been submitted to GenBank and have been assigned the accession numbers AF182198 and AF182199.  by Pucharcos, Carles et al.
Intersectin 2, a new multimodular protein involved in clathrin-mediated
endocytosis1
Carles Pucharcos, Xavier Estivill, Susana de la Luna*
Down Syndrome Research Group, Medical and Molecular Genetics Center, IRO, Hospital Duran i Reynals, Avia. de Castelldefels Km 2.7,
L’Hospitalet de Llobregat, 08907 Barcelona, Spain
Received 2 May 2000; received in revised form 16 June 2000
Edited by Felix Wieland
Abstract Intersectin 1 (ITSN1) is a binding partner of dynamin
that has been shown to participate in clathrin-mediated
endocytosis. Here we report the characterization of a new
human gene, ITSN2, highly similar to ITSN1. Alternative
splicing of ITSN2 generates a short isoform with two EH
domains, a coiled-coil region and five SH3 domains, and a longer
isoform containing extra carboxy domains (DH, PH and C2
domains), suggesting that it could act as a guanine nucleotide
exchange factor for Rho-like GTPases. ITSN2 expression
analysis indicates that it is widely expressed in human tissues.
Intersectin 2 isoforms show a subcellular distribution similar to
other components of the endocytic machinery and co-localize
with Eps15. Moreover, their overexpression, as well as the
corresponding ITSN1 protein forms, inhibits transferrin
internalization. ß 2000 Federation of European Biochemical
Societies. Published by Elsevier Science B.V. All rights re-
served.
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1. Introduction
The clathrin-mediated endocytosis pathway occurring at the
plasma membrane of eukaryotic cells plays a crucial role in
synaptic vesicle recycling in neurons, as well as in the internal-
ization of receptor^ligand complexes and the maintenance of
membrane identity in all cells. The uptake process mediated
by clathrin-coated vesicles (CCVs) seems to require the coor-
dinated interaction of many proteins to form large macromo-
lecular complexes, and even though a growing list of proteins
involved in CCV formation has emerged in recent years, the
precise mechanism of this process remains unknown (reviewed
in [1^3]).
The main structural component of CCVs is the 190-kDa
protein clathrin heavy chain, which when associated with a
25-kDa clathrin light chain forms complexes called triskelions.
The triskelions can organize themselves into a caged lattice
forming the sca¡old of the nascent CCVs [4]. Clathrin is re-
cruited to the plasma membrane by the adapter protein AP-2,
a heterotetramer that recognizes the signals present at the
cytoplasmic tails of membrane proteins [5]. AP-2 also binds
to Eps15 [6,7], epsin [8], amphiphysin heterodimers [9,10],
auxilin [11] and AP180 [12]. The interaction occurs through
the AP-2 K-adaptin appendage domain and a conserved DPF/
W (aspartate-proline-phenylalanine/tryptophan) motif present
in the ligands [11]. All these molecules participate not only in
the rearrangement of the clathrin coat, but also act as anten-
nae to attract other proteins to the growing CCVs. The ¢ssion
of the clathrin-coated invaginated pit into free vesicles is
thought to be mediated by the GTPase dynamin, which oli-
gomerizes itself forming a helical collar around the neck of the
endocytic pits [13,14]. The carboxy-end of dynamin contains a
proline/arginine-rich domain able to interact with several SH3
(Src3 homology) domain-containing proteins including am-
phiphysin I and II, endophilin, syndapin and intersectin (re-
viewed in [3,15]).
Human intersectin is a multimodular protein containing
two EH (Eps15 homology) domains, a central coiled-coil re-
gion and ¢ve consecutive SH3 domains. It exists also as a
longer isoform, mainly expressed in brain, with an extended
carboxy-end region composed of a DH (Dbl homology), a PH
(pleckstrin homology) and a C2 domain [16,17]. Intersectin
orthologues have been identi¢ed in rat (named EHSH1
[18]), mouse (named Ese1 [19]), Xenopus laevis [20] and Dro-
sophila melanogaster (named Dap160 [21]). The short isoform
of intersectin binds to several molecules involved in clathrin-
mediated endocytosis through its di¡erent domains. Thus, the
EH domains bind to epsins [19,20], the coiled-coil region in-
teracts with the central region of Eps15 and Eps15R [19], and
the SH3 domains interact with dynamin [18^20] and synapto-
janin [18,20]. Intersectin has also been proposed to be a con-
nection between endocytosis and exocytosis since its coiled-
coil region binds to SNAP25 and SNAP23 [18]. The ability of
intersectin to interact with multiple components of the endo-
cytic and exocytic machinery leads to the suggestion that it
acts as a sca¡olding protein necessary for the formation of
CCVs.
We have isolated a new human gene encoding for intersec-
tin 2 (ITSN2), a putative paralogue gene of intersectin (which
we herein will name intersectin 1, ITSN1). ITSN2 is expressed
as two main forms likely resulting from alternative splicing
events. The intersectin 2 multimodular composition, the high
degree of similarity with intersectin 1 and its subcellular local-
ization suggest a role in clathrin-mediated endocytosis, a fact
that we have con¢rmed by showing that its overexpression
inhibits transferrin uptake.
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2. Materials and methods
2.1. cDNA cloning and sequencing
In silico searches were performed using BLAST2 programs [22] at
the National Center for Biotechnology Information (NCBI) against
dbest with default parameters (http://www.ncbi.nlm.nih.gov). The ex-
pressed sequence tags (ESTs) were assembled into clusters using the
Sequencher software (Gene Codes Corporation). cDNA was synthe-
sized by reverse transcription of 3 Wg of total human fetal brain and
0.5 Wg of human fetal liver poly(A) RNA (Clontech, Palo Alto, CA,
USA) using the Ready-to-Go kit (Amersham Pharmacia Biotech,
Uppsala, Sweden) and random hexamers as primers, according to
the manufacturer’s recommendations. 1 Wl of the cDNA was used
as a template in three independent PCR reactions with primers de-
signed on the in silico DNA: IT2-1f (238^266) and IT2-2r (1959^
1939), IT2-3f (1840^1860) and IT2-4r (3291^3271), and IT2-16f
(3236^3255) and IT2-17r (4915^4895). The positions of the primers
listed in this section are given in brackets according to sequence in
Fig. 1A; the f or r included in the name indicates the sense in the
nucleotide sequence (f: forward; r: reverse). Rapid ampli¢cation of
5P-ends (5P-RACE) was carried out using the Marathon Ready cDNA
kit (Clontech) from human fetal and adult brain with primer IT2-9r
(1192^1173) as the gene-speci¢c primer (GSP), and primer IT2-21r
(630^609) as the nested speci¢c primer (NSP). Two di¡erent
3P-RACE reactions were performed with the same kit and the follow-
ing pairs of primers: IT2-16f (3236^3255) as GSP and IT2-20f (4801^
4822) as NSP, and IT2-16f as GSP and IT2-18f (3715^3734) as NSP,
respectively. Reactions were carried out as described in the manufac-
turer’s protocol. RT-PCR and RACE products were cloned in
pGEM-T Easy (Promega, Madison, WI, USA) and their DNA se-
quence determined with an ABI dye terminator cycle sequencing-
ready reaction kit (Perkin Elmer, Foster City, CA, USA) and an
automated DNA sequence analyzer ABI-Prism 377 XL Upgrade (Per-
kin Elmer).
Protein analysis for domain and pattern recognition was carried
out using the following public programs: Pro¢lescan (http://www.
isrec.isb-sib.ch/software/PFSCAN_form.html), SMART ([23]; http://
smart.EMBL-Heidelberg.de) and COILS2 (http://www.isrec.isb-sib.
ch/software/COILS_form.html).
2.2. Northern blotting
Northern blots containing poly(A) RNA from human adult tissues
(Cat. No. 7760-1), human fetal tissues (Cat. No. 7756-1) and di¡erent
human brain sections (Cat. No. 7769-1) were purchased from Clon-
tech. Northern blots were hybridized following the manufacturer’s
recommendations with the probes indicated in Section 3 labelled by
random priming. Blots were washed sequentially in 2USSC/0.1%
SDS, 0.2USSC/0.1% SDS and 0.1USSC/0.1% SDS, at 65‡C for 20
min each and exposed to X-ray ¢lm for 2^5 days at 370‡C.
2.3. Vector construction
The di¡erent ITSN2 open reading frames were subcloned as N-
terminal HA-tagged fusions in the pCDNA-HA1 expression vector
[24]. The N-terminus of the long isoform was generated by PCR
with the forward primer IT2BamHI/ATG (5P-GGATCCGCT-
CAGTTTCCCACAGCT-3P) and the reverse primer IT2-21r, then di-
gested with BamHI/SalI and cloned into pCDNA3-HA1. The rest of
the sequence was extended by ligating a HindIII-HindIII fragment
and a HindIII-BstXI fragment obtained from the cDNA clones de-
scribed in Section 3.
To generate the short isoform, the 3P-end of ITSN2-L from nucle-
otide 3279 to end, in pCDNA3-HA1, was replaced by a BstEII-XbaI
fragment containing the speci¢c 3P-end of ITSN2-S, generated by PCR
with the forward primer IT2-16f and the reverse primer IT2XbaI/Stop
(5P-GCTCTAGAACCATCTCTCATGAGA-3P).
Plasmids containing the open reading frames of ITSN1-S and
ITSN-L were generated subcloning the corresponding cDNA frag-
ments [17] into pCDNA3-HA1 with the 5P-end of ITSN1 generated
by PRC with primers IT1BamHI/ATG (5P-CGCGGATCCATGGCT-
CAGTTTCCA-3P) and 76-26 (5P-ATTCCGTTCCCACTCAAGT-3P).
2.4. Protein expression analysis
COS-7 cells were grown and maintained in Dulbecco’s modi¢ed
Eagle’s medium (DMEM) supplemented with 5% fetal bovine serum
(FBS) and antibiotics. Transfections were carried out with Lipofectin
(Life Technologies, Rockville, MA, USA) following the manufactur-
er’s instructions. Cells were harvested and processed at a ¢nal time of
48 h post-transfection.
Protein expression was checked by Western blotting using total cell
extracts. Brie£y, transfected cells were harvested in phosphate-bu¡-
ered saline (PBS) and cell pellets resuspended in Laemmli^SDS bu¡er.
Cell extracts were run on 7.5% SDS^PAGE gels and transferred to
Immobilon-P membranes (Millipore, Bedford, MA, USA). Filters
were blocked in 10% dry milk powder/0.05% Tween-20 in PBS, and
HA-tagged proteins detected with the anti-HA monoclonal antibody
HA.11 (BabCo, Richmond, CA, USA) and enhanced chemilumines-
cence (WestPico Chemiluminescent Substrate, Pierce, Rockford, IL,
USA).
2.5. Immuno£uorescence and transferrin internalization assay
For immuno£uorescence experiments, approximately 3U105 COS-7
cells were plated on 60-mm dishes containing 12-mm coverslips. Cells
were transfected using 10 Wg of Lipofectin (Life Technologies) togeth-
er with 5 Wg of recombinant plasmids in serum-free DMEM, and 16 h
after transfection cells were washed with DMEM and incubated for
another 30 h in DMEM with 5% of FBS.
Cells on coverslips were washed in PBS, ¢xed in 4% paraformalde-
hyde for 15 min at room temperature, permeabilized in 0.1% Triton
X-100 for 10 min and blocked in PBS^10% FBS for 30 min. Cells
were incubated with the primary antibodies in PBS^1% FBS for 1 h,
washed intensively in PBS^1% FBS, then incubated with the second-
ary antibodies in PBS^10% FBS for 45 min and washed again with
PBS^1% FBS. Coverslips were mounted using Citi£uor (Citi£uor Ltd,
Cambridge, UK) and analyzed on an Olympus microscope BX60. As
primary antibodies we used the anti-HA monoclonal antibody HA.11
(1 Wg/ml) and a rabbit polyclonal anti-Eps15 (1 Wg/ml; #C20, Santa
Cruz Biotechnology, Santa Cruz, CA, USA). The secondary antibod-
ies used were a goat anti-mouse £uorescein isothiocyanate (FITC)-
conjugated antibody and a goat anti-rabbit Cy3-conjugated antibody
(1:250; Amersham Pharmacia Biotech).
For the transferrin uptake assay, transfected cells were washed
three times with serum-free DMEM, incubated for 1 h in serum-free
DMEM, and then incubated for 25 min in DMEM containing 75 nM
tetramethylrhodamine isothiocyanate (TRITC)-conjugated transferrin
(Molecular Probes, Eugene, OR, USA) and 1 mg/ml bovine serum
albumin. After washing thoroughly with PBS to reduce non-speci¢c
staining, cells were ¢xed, permeabilized and incubated with the anti-
HA antibody as described above, in order to identify the transfected
cells.
3. Results and discussion
3.1. Cloning of the human intersectin 2 cDNA
The use of ITSN1 [17] as a template in BLAST searches
against the human EST database identi¢ed several ESTs
highly similar but not identical, suggesting the existence of a
novel human gene. The ESTs were grouped in four independ-
ent clusters along the coding region of the ITSN1 long iso-
form, allowing us to design primers in each one of the clusters
to produce overlapping cDNA fragments. RT-PCR reactions
using the combination of primers indicated in Section 2 on
RNA from two di¡erent human tissues, brain and liver, ren-
dered DNA fragments of the expected sizes and several clones
were sequenced for each case. To isolate the full-length
cDNA, we carried out two nested RACE reactions with prim-
ers IT2-9r and IT2-21r (5P-RACE) and IT2-16f and IT2-20f
(3P-RACE). The assembly of the RT-PCR and RACE clones
gave rise to a continuous 6091 bp long cDNA with an open
reading frame of 1696 amino acids (Fig. 1A). Since this cDNA
is highly similar all along its sequence to ITSN1, we propose
to name this new gene ITSN2 (accepted by the Human Gene
Nomenclature Committee). There are two putative consecu-
tive translation initiation codons preceded by an in-frame stop
codon, but we favor the second one at nucleotide 241 because
it presents a better consensus sequence for eukaryotic initia-
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Fig. 1. Nucleotide and amino acid sequence of human ITSN2 isoforms. A: Nucleotide and deduced amino acid sequence of ITSN2-L. Nucleo-
tides and amino acid residues are numbered in the right margin. Potential initiation and stop codon and putative ¢rst methionine are in bold.
The stop codon preceding the initiating ATG is indicated with a star. Putative polyadenylation signals are double underlined. Lines above the
nucleotide sequence indicate primers used for the cloning strategy. B: Nucleotide and amino acid sequence of the 3P-end of ITSN2-S1 showing
the alternative 3P-UTR. The short fragment of 15 amino acids speci¢c of intersectin 2-S1 is waved underlined. C: Partial nucleotide and amino
acid sequence of the 3P-end of ITSN2-S2 showing the alternative 3P-UTR. The 3P-UTR full sequence has 3268 nucleotides and corresponds to
the SH3P18 cDNA sequence (GenBank accession number U61167).
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tion of translation (CC[G/A]CCATGG [25]). Two consensus
polyadenylation signals (AATAAA) are found at nucleotide
positions 5824 and 6067, in the 763 bp long 3P-untranslated
region (UTR) (Fig. 1A).
ITSN1 is expressed as two major alternative spliced tran-
scripts that di¡er in their 3P-ends [16,17]. To look for the
existence of a shorter isoform in ITSN2, we carried out a
3P-RACE reaction with primers IT2-16f and IT2-18f and iso-
lated several clones with a di¡erent 3P-end. The new cDNA
gave rise to an open reading frame of 1248 amino acids, with
only 15 amino acids not present in the long open reading
frame (Fig. 1B). In spite of all the isolated clones having
poly(A) tails, no clear polyadenylation signals were found in
their 3P-UTRs. A partial sequence of human ITSN2 was rep-
resented in the cDNA clone SH3P18 ([26], GenBank accession
number U61167), which would generate a di¡erent short open
reading frame (Fig. 1C) lacking 57 amino acids and equivalent
to the previously described short isoform of intersectin 1
(ITSN1). We will refer to the di¡erent protein isoforms as
intersectin 2-L (ITSN2-L, GenBank accession number
AF182198) and intersectin 2-S1 (ITSN2-S, GenBank acces-
sion number AF182199) for the long and short isoforms, re-
spectively, and intersectin 2-S2 for the isoform represented by
SH3P18.
3.2. ITSN2 expression analysis
To determine the expression pattern of ITSN2, we have
hybridized Northern blots containing mRNA from di¡erent
fetal and adult human tissues, using a probe spanning nucleo-
tides 304^1887 (probe S) common to the short and long
ITSN2 isoforms. The assay revealed the presence of three
major transcripts of approximately 6.5, 8 and 10 kb in all
the human tissues tested, but with di¡erences in the total
amount and ratio among the three expressed bands (named
3, 2 and 1 in Fig. 2A, panels 1, 2 and 3). The 10-kb transcript,
primarily expressed in adult heart and liver, is present in all
the tissues, although it is only detectable with longer expo-
sures (data not shown). To ¢nd out which of the transcripts
corresponded to the long isoform, we hybridized the same set
of blots with probe L (nucleotides 4906^5912 in Fig. 1A). In
this case, only the 6.5- and 10-kb mRNA species were ob-
served in all the tissues (bands 3 and 1 in Fig. 2B, panels 1,
2 and 3). Probe L also detected a minor band of approxi-
mately 3 kb in fetal and adult lung not present in probe S
membranes (Fig. 2B, panels 1 and 3), suggesting that this
transcript may contain only the C-terminal subset of the do-
mains described below (Fig. 3A). Interestingly, despite both
probes detecting the same band pattern in adult and fetal
tissues, di¡erences in the band ratio could be observed.
Fig. 2. Expression analysis of ITSN2. A: Northern blots containing 2 Wg of poly(A) RNA from the human adult tissues (panel 1), human
brain sections (panel 2) and human fetal tissues (panel 3) were hybridized with probe S (nucleotides 304^1887). Arrows point to the three bands
of approximately 6.5, 8 and 10 kb (arrows 1, 2 and 3, respectively) present in all the membranes. B: Membranes described above were hybrid-
ized with an ITSN2-L-speci¢c probe spanning nucleotides 4906^5912 (probe L). Note the absence of the 8-kb transcript (arrow 2). A 3-kb
mRNA is detected in adult and fetal lung.
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Thus, for instance, whereas in fetal brain bands 2 and 3 (short
and long isoform, respectively) presented similar intensity,
band 2 is clearly overexpressed with respect to band 3 in adult
brain (Fig. 2A, panels 1 and 3). Altogether these results in-
dicate that, although widely expressed, ITSN2 expression is
tissue-dependent and likely regulated during development.
Human ITSN1 is expressed as three main transcripts of
approximately 15, 6 and 4.5 kb [16]. In distinction to
ITSN2, the longest one corresponds to the long isoform and
it is expressed almost exclusively in brain, a fact that estab-
lishes a clear di¡erence between both genes.
3.3. ITSN2 protein primary sequence analysis
The multidomain composition of intersectin 2 is schemati-
cally depicted in Fig. 3A. Intersectin 2-S possesses two EH
domains at positions 15^108 and 237^331 which share 52.7%
similarity between them, and 87.1% and 72.6% for EH1 and
EH2, respectively, when compared with the equivalent EH
domains in human intersectin 1. The EH domains are fol-
lowed by a region almost entirely composed of glutamic
acid (18.9%), lysine (15%), leucine (14.5%), glutamine
(11.3%) and arginine (9.3%), which is predicted to be a
coiled-coil region. Although this is one of the less conserved
regions between intersectin 1 and 2, the amino acid composi-
tion is highly similar.
The central part of the protein has ¢ve consecutive SH3
domains named A^E, respectively (Fig. 3A). The open reading
frame of intersectin 2-S ¢nishes after the last SH3 domain
(SH3-E), and may extend 57 amino acids when compared to
intersectin 1-S, depending on which alternative splicing occurs
(Fig. 1B,C). The level of conservation between each SH3 do-
main of intersectin 1 and 2 is high (more than 80% similarity),
Fig. 3. Multimodular protein analysis and expression of intersectins. A: Schematic representation of intersectin 2-S and intersectin 2-L showing
its multimodular structure. Domains are represented as boxes and numbers below them show the domain position in the amino acid sequence.
B: Expression of human intersectins. Extracts of COS-7 cells transfected with pCDNA3-HA1/ITSN2-S, /ITSN2-L, /ITSN1-S and /ITSN1-L, or
mock-transfected (3), were analyzed by Western blot. Tagged proteins were detected with an anti-HA antibody. Size markers in kDa are
shown.
C
Fig. 4. Subcellular localization of intersectins and transferrin uptake inhibition assay. A: COS-7 cells transiently transfected with pCDNA3-
HA1/ITSN2-S, /ITSN2-L, /ITSN1-S and /ITNS1-L were analyzed by indirect immuno£uorescence with an anti-HA antibody and a secondary
antibody conjugated with FITC (left panels); TRICT transferrin uptake is detected by red staining (central panel). Overlapping images are
shown (right panel). B: Co-localization of ectopically expressed intersectins with endogenous Eps15. COS-7 cells transiently transfected with
pCDNA3-HA1/ITSN2-L and /ITNS1-L were analyzed by indirect immuno£uorescence with anti-HA (green) and anti-Eps15 (red) antibodies as
indicated. Overlapping images are shown (merge: yellow). Some of the co-localizing dots of intersectin 2-L are indicated with arrows. C: Quan-
titation of the e¡ect of intersectin overexpression in the internalization of transferrin expressed as a percentage of transfected COS-7 cells show-
ing normal transferrin uptake. More than 200 transfected cells were counted for each category. Error bars indicate standard deviation of three
experiments.
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except in the case of the SH3A, which is noticeably less con-
served (62% similarity).
The carboxy-terminus speci¢c to the intersectin 2-L isoform
contains three well-described domains. The ¢rst one, from
residues 1212 to 1399, matches a DH domain which usually
functions as the catalytic region of guanine nucleotide ex-
change factors (GEFs) for Rho-like GTPases [27]. Interest-
ingly, all the residues which have been described as important
for its enzymatic activity [28] are present in the intersectin 2
DH domain (L-1228, I-1253, F-1254, I-1287, L-1343, L-1347
and R-1353). As in all the other DH domain-containing pro-
teins, the intersectin 2 DH domain is followed by a PH do-
main with 85.4% similarity between intersectin 1 and 2. Fi-
nally, the most carboxy region of the long isoform has
sequence homology with C2 domains [29], a calcium binding
motif widely distributed among eukaryotic proteins and
thought to be involved in cellular membrane interaction.
We have generated four recombinant plasmids in which the
coding regions of intersectin 2-L and -S, and the equivalent
isoforms of intersectin 1 [17], were cloned as N-terminal HA-
tagged proteins. To check intersectin expression, lysates of
COS-7 cells transfected with the four plasmids were analyzed
by Western blot with an anti-HA antibody. As is shown in
Fig. 3B, expressed tagged proteins migrated in good agree-
ment with their predicted molecular weights: intersectin 2-S,
141.7 kDa; intersectin 2-L, 193.3 kDa; intersectin 1-S, 137.6
kDa and intersectin 1-L, 195.4 kDa.
3.4. Intersectin 2 subcellular localization and endocytosis assay
The same constructs described above were used to transfect
COS-7 cells in order to analyze the subcellular localization of
the fusion proteins (Fig. 4A, left panels). Both intersectin 2
and 1 showed a ¢ne punctate sparse throughout the cytoplasm
that was very similar to the one reported for other compo-
nents of CCVs such as AP-2, Eps15, clathrin or epsin [8,30].
In fact, all the intersectins tested (2-L, 2-S, 1-L and 1-S) co-
localized with endogenous Eps15 (Fig. 4B and data not
shown), comparable to what has been described for Ese1-S
[19]. Despite both intersectins presenting a similar staining
pattern, subtle di¡erences could be appreciated, with a more
marked perinuclear staining for intersectin 1 (two representa-
tive cells are shown in Fig. 4A, left panels), and concentrated
in Golgi-like structures in agreement with what has been re-
ported for the endogenous protein in rat hippocampal neu-
rons [31]. Conversely, we observed no evident staining pattern
di¡erences between the short and long isoforms in either in-
tersectin 1 or 2, as an indication that the protein domains
present in the short isoforms are su⁄cient for mediating
intersectin subcellular distribution. The EH domains have
been pointed to as responsible for the subcellular localiza-
tion of intersectin 1 [31] ; however, the deletion of the SH3
domains in both intersectins promotes the nuclear accumula-
tion of the resulting 60-kDa proteins (data not shown),
suggesting that these domains may be involved in cytosolic
retention and therefore contribute to the proper protein local-
ization.
To test if intersectin 2 is involved in endocytosis, we have
performed a transferrin endocytosis assay. Since endocytosis
is dependent on a ¢ne regulation of the interaction of the
di¡erent proteins involved, altering the relative ratios of
some of the components of the uptake mechanism can disrupt
it. With this reasoning, clathrin-mediated endocytosis of
transferrin has been shown to be inhibited by overexpression
of amphiphysin I and II [10], epsins [32] and Ese1-S [19].
Therefore, we performed a transferrin inhibition uptake assay
in COS-7 cells overexpressing the two isoforms of both inter-
sectins. Untransfected cells gave a punctate, perinuclear red
staining characteristic of the endosomal transferrin internal-
ization pathway. As has been previously described for mouse
Ese1 [19], intersectin 1-S behaved as an inhibitor of transferrin
internalization in this assay. Similarly, overexpression of ei-
ther intersectin 1-L, intersectin 2-S or intersectin 2-L caused a
block of transferrin uptake, scored by the absence of perinu-
clear red staining (Fig. 4A). More than 200 cells were counted
in the analysis, with reproducible results in di¡erent experi-
ments as quantitated in the bar graph (Fig. 4C). The e⁄ciency
of the blockade was very similar for the distinct intersectins,
with a slightly higher score for intersectin 2 isoforms. These
data indicate that overexpression of any of the intersectin 2
isoforms can block clathrin-mediated endocytosis, probably
by sequestering binding partners involved in the process.
In the case of intersectin 1 short isoform, this feature has
been associated with its ability to bind CCV-related proteins
such as dynamin [18^20] or synaptojanin [18,20]. In particu-
lar, the intersectin 1 SH3A domain has been described as the
most potent inhibitor of CCV formation in permeabilized
3T3-L1 cells and as such participating in early events, while
the SH3C and SH3E domains were involved in late events of
CCV ¢ssion [33]. These di¡erences probably re£ect the bind-
ing abilities of each domain. We still do not know the binding
partners of intersectin 2, although due to its high amino acid
similarity, it is tempting to speculate that some will be the
same as for intersectin 1. The co-localization of intersectin 2
with endogenous Eps15 indeed con¢rms that this is the case
for this CCV-related molecule. At this point it is worthwhile
to mention that the SH3A domain is the most divergent one
when intersectin 1 and 2 are compared, and that this might
impose di¡erences in its ability of binding dynamin [18,20] or
its recently described partner mSos1 [34]. Future e¡orts
should be directed to ¢nding out the partner speci¢city of
each intersectin and the functional implication of the extra
carboxy-end, a putative GEF for a Rho-like GTPase.
The number of proteins involved in clathrin-mediated en-
docytosis from the plasma membrane has grown dramatically
in the past few years revealing a complex picture of protein^
protein interactions. Intersectin 1 and its paralogous intersec-
tin 2 described here belong to this group of proteins and likely
act as sca¡olding on providing a great variety of interacting
domains.
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